SCHEMBL289969

SCHEMBL289969

c1ccc(CC(OC(Cc2ccccc2)C2CO2)C2CO2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SLC6A2 P23975 2/20 0.36
TAAR1 Q96RJ0 2/20 0.36
MAOA P21397 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CYP2A6 P11509 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289970 1.00 EPHX1 (0.39) EPHX1MEN1KMT2ASLC6A2TAAR1
SCHEMBL334898 1.00 EPHX1 (0.39) EPHX1MEN1KMT2ASLC6A2TAAR1
SCHEMBL9234671 0.81 AGXT (0.34) MEN1KMT2ATAAR1CYP2A6CYP1A2
SCHEMBL3263940 0.81 MEN1 (0.41) MEN1KMT2ATAAR1
SCHEMBL9232952 0.81 SLC18A3 (0.35) TAAR1SIGMAR1
SCHEMBL3276592 0.81 EPHX1 (0.33) EPHX1MEN1KMT2ATDP1CYP1A2
SCHEMBL9234577 0.79 SLC6A4 (0.47) SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL9090132 0.79 TSHR (0.41) EPHX1MEN1KMT2ASLC6A2TAAR1
SCHEMBL6636811 0.79 SRR (0.41) EPHX1CYP1A2
SCHEMBL1099896 0.78 ALDH1A1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024253550-A1 THE METHOD OF PREPARATION OF THE MEDICINAL FORMULATION OF CLOTRIMAZOLE WITH AMPHIPHILIC COPOLYMER AND ITS APPLICATION IN ANTICANCER THERAPY AND COMBINED ANTICANCER THERAPY WITH NIFURATEL. Centrum Badań Molekularnych i Makromolekularnych PAN (PL) 2024-12-12 WO claimed
CN-117777048-B Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 上海科利生物医药有限公司 2024-09-20 CN claimed
CN-117777048-A Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 上海科利生物医药有限公司 2024-03-29 CN claimed
CN-111647200-B Acetal structure-containing flame retardant and preparation method and application thereof 中国科学技术大学 2021-07-06 CN claimed
CN-110327977-B Aluminum-lithium bimetallic catalyst and preparation method and application thereof 山西大学 2021-05-14 CN claimed
EP-2766422-B1 VULCANISABLE COMPOUNDS ON THE BASIS OF NITRILE RUBBERS CONTAINING EPOXY GROUPS ARLANXEO DEUTSCHLAND GMBH (DE) 2017-05-03 EP claimed
US-20040186123-A1 Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline WYETH 2004-09-23 US claimed
US-6693197-B2 Process for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino- [2,3-f] quinoline WYETH 2004-02-17 US claimed
EP-1387845-A2 PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-(2,3-f) QUINOLINE Wyeth (US) 2004-02-11 EP claimed
US-20030134222-A1 Photoresist composition and method of forming pattern using the same SAMSUNG ELECTRONICS CO., LTD. 2003-07-17 US claimed
US-20020187983-A1 Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline WYETH 2002-12-12 US claimed
WO-2002092602-A2 PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE WYETH (US) 2002-11-21 WO claimed
EP-1114065-A1 CELLULOSE MICROFIBRILS WITH MODIFIED SURFACE, PREPARATION METHOD AND USE THEREOF RHODIA CHIMIE (FR) 2001-07-11 EP claimed
WO-2000015667-A1 CELLULOSE MICROFIBRILS WITH MODIFIED SURFACE, PREPARATION METHOD AND USE THEREOF RHODIA CHIMIE (FR) 2000-03-23 WO claimed
US-5476917-A Dispersity of pigments; gloss KOREA CHEMICAL CO., LTD. (KR) 1995-12-19 US claimed
JP-59076039-A None JP disclosed
JP-11240877-A None JP disclosed
JP-S5976039-A (S)-2,3-DIACETYL-1-BENZYL GLYCEROL TOA EIYOU KAGAKU KOGYO KK 1984-04-28 JP disclosed
JP-S5976036-A PREPARATION OF (4S)-4-(P-TOLYL)PENTANAL TOA EIYOU KAGAKU KOGYO KK 1984-04-28 JP disclosed
JP-S57116060-A PREPARATION OF (R)-(-)-5- BENZYLOXYMETHYLTETRAHYDROFURAN-2-ONE KAWAKEN FINE CHEM CO LTD 1982-07-19 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187983-A1 Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline CYP1A1, CYP2F1, CYP1B1 EPHX1 279/4885MEN1 1400/4885KMT2A 1775/4885
US-20040186123-A1 Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline CYP1A1, CYP2F1, CYP1B1 EPHX1 279/4885MEN1 1400/4885KMT2A 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.